Measurement of activities in two different angiotensin II generating systems, chymase and angiotensin-converting enzyme, in the vitreous fluid of vitreoretinal diseases: A possible involvement of chymase in the pathogenesis of macular hole patients

Current Eye Research

Volumn 29, Issue 4-5, 2004, Pages 321-325

  Maruichi, M ^a   Oku, H ^a   Takai, S ^a   Muramatsu, M ^a   Sugiyama, T ^a   Imamura, Y ^a   Minami, M ^a   Ueki, M ^a   Satoh, B ^a   Sakaguchi, M ^a   Miyazaki, Mizou ^a   Ikeda, T ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Chymase; Macular hole; Vitreous fluid

Indexed keywords

ANGIOTENSIN; CHYMASE; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ARTICLE; DIABETIC RETINOPATHY; ENZYME ACTIVITY; EPIRETINAL MEMBRANE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PATHOGENESIS; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA HOLE; VITRECTOMY; VITREORETINOPATHY; VITREOUS BODY;

AGED; ANGIOTENSIN II; CHYMASES; DIABETIC RETINOPATHY; ENZYME ACTIVATION; EPIRETINAL MEMBRANE; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RETINAL DETACHMENT; RETINAL PERFORATIONS; SERINE ENDOPEPTIDASES; VITRECTOMY; VITREOUS BODY;

EID: 19944429674     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680490516161     Document Type: Article

References (32)

1. Wagner J, Jan Danser AH, Derkx FH, de Jong TV, Paul M, Mullins JJ, Schalekamp MA, Ganten D. Demonstration of renin mRNA, angiotensinogen mRNA, and angiotensin converting enzyme mRNA expression in the human eye: Evidence for an intraocular renin-angiotensin system. Br J Ophthalmol. 1996;80:159-163.
2. Kumar A, Rassoli A, Raizada MK. Angiotensinogen gene expression in neuronal and glial cells in primary cultures of rat brain. J Neurosci. 1988;19:287-290.
3. Dzau VJ, Ingelfinger JR, Pratt RE. Regulation of tissue renin and angiotensin gene expressions. J Cardiovasc Pharmacol. 1986;8(suppl 10):S11-16.
4. Paul M, Wagner J, Dzau VJ. Gene expression of the renin angiotensin systems in human tissues. Quantitative analysis by the polymerase chain reaction. J Clin Invest. 1993;91:2058-2064
5. Ferrari-Dileo G, Davis EB, Anderson DR. Angiotensin binding sites in bovine and human retinal blood vessels. Invest Ophthalmol Vis Sci. 1987;28:1747-1751.
6. Matulla B, Streit G, Pieh S, Findl O, Entlicher J, Graselli U, Eichler HG, Wolzt M, Schmetterer L. Effects of losartan on cerebral and ocular circulation in healthy subjects. Br J Clin Pharmacol. 1997;44:369-375.
7. Krejcy K, Wolzt M, Kreuzer C, Breiteneder H, Schutz W, Eichler HG, Schmetterer L. Characterization of angiotensin-II effects on cerebral and ocular circulation by noninvasive methods. Br J Clin Pharmacol. 1997;43:501-508.
8. Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA. Angiotensin levels in the eye. Invest Ophthalmol Vis Sci. 1994;35:1008-1018.
9. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med. 1985;105: 141-145.
10. Otani A, Takagi H, Suzuma K, Honda Y. Angiotensin II potentiates vascular endothelial growth factor-induced angiogenic activity in retinal microcapillary endothelial cells. Circ Res. 1998;82:619-628.
11. Wilkinson-Berka JL, Kelly DJ, Gilbert RE. The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. J Vasc Res. 2001;38:527-535.
12. Takai S, Miyazaki M. The role of chymase in vascular proliferation. Drug News Perspect. 2002;15:278-282.
13. Shiota N, Saegusa Y, Nishimura K, Miyazaki M. Angiotensin II-generating system in dog and monkey ocular tissues. Clin Exp Pharmacol Physiol. 1997;24: 243-248.
14. Kofford MW, Schwartz LB, Schechter NM, Yager DR, Diegelmann RF, Graham MF. Cleavage of type I procollagen by human mast cell chymase initiates collagen fibril formation and generates a unique carboxyl-terminal propeptide. J Biol Chem. 1997;272:7127-7131.
15. Lees M, Taylar DJ, Woolley DE. Mast cell proteinases activate precursor forms of collagenase and stromelysin, but not of gelatinase A and B. Eur J Biochem. 1994;223:171-177.
16. Frank BT, Rossall JC, Caughey GH, Fang KC. Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase. J Immunol. 2001;166:2783-2792.
17. Takai S, Yuda A, Jin D, Nishimoto M, Sakagichi M, Sasaki S, Miyazaki M. Inhibition of chymase reduces vascular proliferation in dog grafted veins. FEBS Lett. 2000;467:141-144.
18. Takai S, Kim S, Sakonjo H, Miyazaki M. Mechanisms of angiotensin II type 1 receptor blocker for anti-atherosclerotic effect in monkeys fed a high-cholesterol diet. J Hypertens. 2003;21:361-369.
19. Constad WH, Fiore P, Samson C, Cinotti AA. Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma. Am J Ophthalmol. 1988;105:674-677.
20. Tamarat R, Silvestre JS, Durie M, Levy BI. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways. Lab Invest. 2002;82:747-756.
21. Funatsu H, Yamashita H, Nakanishi Y, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol. 2002;86:311-315.
22. Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, de Jong PT, Schalekamp MA. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab. 1989:68:160-167.
23. Kishi S, Hagimura N, Shimizu K. The role of the premacular liquefied pocket and premacular vitreous cortex in idiopathic macular hole development. Am J Ophthalmol. 1996;122:622-628.
24. Johnson RN, Gass JD. Idiopathic macular holes. Observations, stages of formation, and implications for surgical intervention. Ophthalmology. 1988;95:917-924.
25. Johnson MW, Van Newkirk MR, Meyer KA. Perifoveal vitreous detachment is the primary pathogenic event in idiopathic macular hole formation. Arch Ophthalmol. 2001;119:215-222.
26. Knupp C, Munro PMG, Luther PK, Ezra E, Squire JM. Structure of abnormal molecular assemblies (collagen VI) associated with human full thickness macular holes. J Struct Biol. 2000;129:38-47.
27. Nicovani S, Rudolph MI. Estrogen receptors in mast cells from arterial walls. Biocell. 2002;26:15-24.
28. May CA. Mast cell heterogeneity in the human uvea. Histochem Cell Biol. 1999;112:381-386.
29. Miller ST, Barney NP, Gamache DA, Spellman JM, Yanni JM. Secretory response of mast cells contained in monodispersed human choroidal preparations. Int Arch Allergy Immunol. 1997;114:139-143.
30. Bishop PN. Structural macromolecules and supramolecular organization of the vitreous gel. Prog Retin Eye Res. 2000;19:323-344.
31. Shepherd RK, Linden J, Duling BR. Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. Circ Res. 1996;78:627-634.
32. Ghiardi GJ, Gidday JM, Roth S. The purine nucleoside adenosine in retinal ischemia-reperfusion injury. Vision Res. 1999;39:2519-2535.